MXPA05010515A - Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba. - Google Patents

Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.

Info

Publication number
MXPA05010515A
MXPA05010515A MXPA05010515A MXPA05010515A MXPA05010515A MX PA05010515 A MXPA05010515 A MX PA05010515A MX PA05010515 A MXPA05010515 A MX PA05010515A MX PA05010515 A MXPA05010515 A MX PA05010515A MX PA05010515 A MXPA05010515 A MX PA05010515A
Authority
MX
Mexico
Prior art keywords
prodrugs
treating
hot flashes
gaba analogs
preventing hot
Prior art date
Application number
MXPA05010515A
Other languages
English (en)
Inventor
Mark A Gallop
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of MXPA05010515A publication Critical patent/MXPA05010515A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Se revelan metodos de uso de profarmacos de analogos de GABA y composiciones farmaceuticos de los mismos para tratar o prevenir sofocos calientes en humanos y composiciones farmaceuticas de profarmacos de analogos de GABA utiles en el tratamiento o prevencion de sofocos calientes.
MXPA05010515A 2003-03-31 2004-03-31 Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba. MXPA05010515A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45947203P 2003-03-31 2003-03-31
US51228003P 2003-10-17 2003-10-17
US53872404P 2004-01-22 2004-01-22
PCT/US2004/010137 WO2004089289A2 (en) 2003-03-31 2004-03-31 Treating or preventing hot flashes using prodrugs of gaba analogs

Publications (1)

Publication Number Publication Date
MXPA05010515A true MXPA05010515A (es) 2006-03-10

Family

ID=33162980

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05010515A MXPA05010515A (es) 2003-03-31 2004-03-31 Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.

Country Status (10)

Country Link
US (1) US20040254246A1 (es)
EP (1) EP1608357A4 (es)
JP (1) JP2006522146A (es)
KR (1) KR20050119676A (es)
AU (1) AU2004227995B2 (es)
CA (1) CA2520468A1 (es)
MX (1) MXPA05010515A (es)
NO (1) NO20055000L (es)
NZ (1) NZ543138A (es)
WO (1) WO2004089289A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
JP2007505149A (ja) * 2003-09-11 2007-03-08 ゼノポート，インコーポレイティド ギャバ類似体のプロドラッグを用いる尿失禁の治療および／あるいは予防
CN1867322B (zh) 2003-10-14 2014-06-25 什诺波特有限公司 结晶形式的γ-氨基丁酸类似物
US20050209319A1 (en) * 2004-03-18 2005-09-22 Xenoport, Inc. Treatment of local pain
CN102429882B (zh) * 2004-11-04 2015-03-25 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
EP2101752A1 (en) * 2006-12-08 2009-09-23 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
TWI369982B (en) * 2007-01-11 2012-08-11 Xenoport Inc Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
CA2710538A1 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2009094563A2 (en) * 2008-01-25 2009-07-30 Xenoport, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use
GB0810990D0 (en) 2008-06-16 2008-07-23 Q Chip Ltd Device and method of making solid beads
US8299291B2 (en) 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US7989641B2 (en) 2008-08-07 2011-08-02 Xenoport, Inc. Methods of synthesizing N-hydroxysuccinimidyl carbonates
WO2010101115A1 (ja) * 2009-03-02 2010-09-10 アステラス製薬株式会社 固形製剤の包装体
CA2753057C (en) * 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
WO2014134005A2 (en) 2013-02-26 2014-09-04 Xenoport, Inc. Method of making 1-(acyloxy)-alkyl carbamate compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) * 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) * 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) * 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) * 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) * 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) * 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) * 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) * 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4820523A (en) * 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
ES2169848T3 (es) * 1996-03-14 2002-07-16 Warner Lambert Co Nuevos aminoacidos ciclicos coronados como agentes farmaceuticos.
US6103932A (en) * 1996-03-14 2000-08-15 Warner-Lambert Company Substituted cyclic amino acids as pharmaceutical agents
US6375987B1 (en) * 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
FR2779651B1 (fr) * 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) * 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
PT1202725E (pt) * 1999-07-22 2007-07-11 Universuty Of Rochester Método para tratar sintomas de alteração hormonal, incluindo afrontamentos.
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
IL159300A0 (en) * 2001-06-11 2004-06-01 Xenoport Inc Prodrugs of gaba analogs, compositions and uses thereof
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
MXPA05006320A (es) * 2002-12-13 2005-08-26 Warner Lambert Co Derivados de pregabalina para el tratamiento de fibromialgia y otros trastornos.

Also Published As

Publication number Publication date
NO20055000D0 (no) 2005-10-27
EP1608357A2 (en) 2005-12-28
KR20050119676A (ko) 2005-12-21
WO2004089289A3 (en) 2005-03-10
WO2004089289A2 (en) 2004-10-21
EP1608357A4 (en) 2008-03-26
US20040254246A1 (en) 2004-12-16
CA2520468A1 (en) 2004-10-21
NZ543138A (en) 2009-02-28
JP2006522146A (ja) 2006-09-28
AU2004227995A1 (en) 2004-10-21
AU2004227995B2 (en) 2010-06-03
NO20055000L (no) 2005-12-29

Similar Documents

Publication Publication Date Title
MXPA05010515A (es) Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
MX2009005114A (es) Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
SG146643A1 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
IL172194A0 (en) Methods and compositions for treating amyloid-related diseases
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
ATE329587T1 (de) Zusammensetzungen zur verwendung bei der behandlung der osteoporose und/oder der entzündlichen gelenkerkrankungen
EP1816996A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING PLANT EXTRACTS FOR THE TREATMENT OF CANCER
GB2421260B (en) Well treating compositions for slow release of treatment agents and methods of using the same
DK1169060T3 (da) Natriumkanalblokkerpræparater og anvendelse deraf
AU8490901A (en) Urea compounds and methods of uses
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
UA92907C2 (uk) Похідні тетрагідроіндазолону
TW200639172A (en) Pyrazolopyridines and analogs thereof
IL164370A0 (en) Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
UA100702C2 (ru) Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина
MY148647A (en) Pharmaceutical compositions comprising a camtothecin derivative
EP1703907A4 (en) COMPOSITIONS AND METHODS FOR TREATING RECURRENT CONDITIONS
WO2007027476A3 (en) Treating premature ejaculation using gabapentin and pregabalin prodrugs
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
DOP2003000621A (es) Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa
EA200801731A1 (ru) Составы и способы лечения тробмоцитемии
ATE473277T1 (de) Zusammensetzungen und verfahren zur prävention und behandlung von immunvermittelten entzündungskrankheiten
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.

Legal Events

Date Code Title Description
FG Grant or registration